SLXN SILEXION THERAPEUTICS CORP

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit

Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management, including CEO Ilan Hadar, will attend the 7th RNAi-Based Therapeutics Summit, taking place January 27-29 in Boston, MA.  

The 7th RNAi-Based Therapeutics Summit is the industry's premier forum inviting drug developers to discuss RNA-based therapeutics for neurological, metabolic, cardiovascular, and oncological diseases. Silexion is developing SIL204, a next-generation siRNA therapy designed to silence mutated KRAS oncogenes - the most common oncogenic driver in human cancers. SIL204 is planned to enter a Phase 2/3 clinical study program in locally advanced pancreatic cancer in mid 2026.

Silexion management will host one-on-one meetings during the summit. Interested parties should contact the Company’s Investor Relations representatives who can arrange such meetings.

Silexion is pleased to be an official partner of the RNAi-Based Therapeutics Summit for 2026.



About Silexion Therapuetics

Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer. For more information please visit:

Company Contact:

Silexion Therapeutics Corp

Ms. Mirit Horenshtein Hadar, CFO

Investor Relations

Arx Investor Relations

North American Equities Desk



EN
21/01/2026

Underlying

SLXNSILEXION THERAPEUTICS CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SILEXION THERAPEUTICS CORP

 PRESS RELEASE
Free
SLXN SILEXION THERAP...

Silexion Therapeutics Receives Approval from Israeli Ministry of Healt...

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting highly prevalent KRAS-driven cancers with significant unmet medical need Company reported strong positive preclinical study results demonstrating significant anti-tumor activity in multiple models and announced successful completion of toxic...

March 24, 2026 1 EN
 PRESS RELEASE
Free
SLXN SILEXION THERAP...

Silexion Therapeutics Receives Approval from Israeli Ministry of Healt...

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting highly prevalent KRAS-driven cancers with significant unmet medical need Company reported strong positive preclinical study results demonstrating significant anti-tumor activity in multiple models and announced successful completion of toxic...

March 24, 2026 1 EN
 PRESS RELEASE
Free
SLXN SILEXION THERAP...

Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financ...

Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer, reinforcing broad therapeutic potential During the fourth quarter, Silexion achieved key clinical readiness milestones including completing two-species toxicology studies, written Scientific Advice from Germany's BfArM, and submission of Phase 2/3 clinical trial application to the M...

March 17, 2026 1 EN
 PRESS RELEASE
Free
SLXN SILEXION THERAP...

Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Ext...

Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting Grand Cayman, Cayman Island, March 05, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, reminds its shareholders of the upcoming Extraordinary General Meeting of Shareholders (the "EGM"), scheduled to be held on March 16, 2026. At the EGM, shareholders will be asked to vote on proposals relating to:  Authorized Share Capital Increase Proposal: An increase to the authorized share capital of the Compan...

March 5, 2026 1 EN
 PRESS RELEASE
Free
SLXN SILEXION THERAP...

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Sum...

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management, including CEO Ilan Hadar, will attend the 7th RNAi-Based Therapeutics Summit, taking place January 27-29 in Boston, MA.   The 7th RNAi-Based Therapeutics Summit is the industry's premier forum inviting drug developers to discuss RNA-based therapeutics for neurological, metabolic, cardiovascular, an...

January 21, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch